ENTITY
Sihuan Pharmaceutical Hldgs

Sihuan Pharmaceutical Hldgs (460 HK)

44
Analysis
Health CareChina
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
more
Refresh
21 Feb 2024 23:19

China Traditional Chinese Medicine (570 HK): Sinopharm-Led Pre-Conditional Offer at HK$4.60

The offer is attractive to historical trading ranges and peer multiples. Ping An, which holds a blocking stake, will be supportive. This looks like...

Logo
422 Views
Share
07 Feb 2024 22:14

China Traditional Chinese Med (570 HK): Third Time's the Charm as Sinopharm Revives Its Interest?

Due to Sinopharm's previous privatisation attempts, shareholders will be wary of the latest rumour. Nevertheless, the valuation is undemanding...

Logo
328 Views
Share

United Laboratories International Holdings Placement (3933.HK) - Valuation Pullback Seems Inevitable

United Lab is facing a performance decline when the dividend period of the pandemic has subsided. Weight management/veterinary drug businesses have...

Logo
433 Views
Share
10 Feb 2023 08:55

Shanghai Haohai Biological Technology (688366.CH/6826.HK)- Disappointing Earnings and Gloomy Outlook

Continuous M&A fails to bring ideal performance to Haohai. Medical aesthetics is the main growth driver, but Haohai is lack of competitiveness....

Logo
286 Views
Share
29 Nov 2022 08:45

Sihuan Pharmaceutical (460.HK) - About the Recent Business Adjustments and the Outlook

Sihuan's pursuing strategic adjustments actively, but its business transformation may not end up well without persuasive long logic. We recommend...

Logo
274 Views
Share
x